What Pfizer (PFE) investors can see in the recent performance

Pfizer (PFE) has seen its stock edge up around 0.2% in the past day and about 0.7% over the past week, with a one-month gain of roughly 1% but a decline of about 1.4% over the past three months.

With the share price at $26.21, Pfizer has a modest positive year to date share price return of 4.1%, while the 1 year total shareholder return of 14.3% contrasts with a weaker 3 year record.

If Pfizer has you thinking about healthcare opportunities more broadly, this could be a good moment to scan other potential ideas using our healthcare focused 40 healthcare AI stocks

With a recent share price near $26 and mixed multi year returns, the key question is whether Pfizer’s current valuation and intrinsic discount hint at mispricing or if the market already reflects its future growth potential.

Most Popular Narrative: 6.4% Undervalued

Pfizer's most followed narrative, according to Valrodmon, places fair value at $28, slightly above the recent $26.21 share price and framing a modest discount that hinges on how the transition beyond its pandemic products plays out.

No final de 2025, a Pfizer Inc. (PFE) encontra-se em um momento pivotal de sua história. Após o boom extraordinário impulsionado pela vacina Comirnaty e pelo antiviral Paxlovid durante a pandemia, a empresa agora navega por águas mais calmas e turbulentas. Os analistas de Wall Street, com um consenso geral de "Hold" e um preço-alvo médio em torno de US$ 28-30 para os próximos 12 meses (representando um upside modesto de 10-20% a partir dos níveis atuais próximos a US$ 25), veem a Pfizer como uma ação de valor defensiva, com alto dividend yield (acima de 6%), mas sem explosão de crescimento imediato. O futuro, segundo eles, será marcado por desafios de curto prazo, como o declínio das vendas de produtos COVID e o temido "patent cliff", mas com potencial de recuperação a médio e longo prazo graças a um pipeline robusto e aquisições estratégicas.

Curious how a company facing a patent cliff, falling COVID revenue and a heavy acquisition bill still lands on an undervalued fair value. The narrative leans heavily on a packed late stage pipeline, margin rebuild and capital returns to justify that $28 figure. The tension between declining near term forecasts and longer term product launches is exactly where this valuation gets interesting.

Result: Fair Value of $28 (UNDERVALUED)

However, this hinges on Pfizer offsetting its patent cliff and COVID revenue drag, as well as on the acquired pipeline actually translating into commercially meaningful products.

Another way to look at Pfizer's valuation

While the user narrative leans on a $28 fair value, the market is sending a different message through Pfizer's P/E ratio. At about 20x earnings, the stock trades above the US pharmaceuticals average of 15.2x and slightly above its own fair ratio of 19.4x, yet below the 25.6x peer average. That mix of premium and discount raises a simple question: is the risk skewed toward a re rating down to the fair ratio or up toward peers?

Next Steps

With sentiment split between opportunity and caution, this is a good moment to look through the latest data yourself and decide where you stand. To weigh both sides in one place, start with the 1 key reward and 4 important warning signs

Looking for more investment ideas?

If you stop at one stock, you may miss broader opportunities. Use the Simply Wall Street Screener to surface fresh ideas that fit your style.

• Target higher income potential by scanning companies that show up as 8 dividend fortresses and see which yields stand out for you.
• Look for quality at a discount by focusing on 44 high quality undervalued stocks that combine solid fundamentals with attractive pricing signals.
• Prioritize resilience by filtering for 70 resilient stocks with low risk scores that aim to keep volatility and balance sheet risks in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.